It has been previously demonstrated that cyclin-dependent kinase inhibitor 2A (CDKN2A/ARF) causes cancer cells to be sensitive to ferroptosis by inhibiting the ability of NRF2 and its transcriptional target SLC7A11 [42] through pathways dependent or independent of p53 tumor suppression gene in the cancerous cells [43, 44]. Here, TP53 is linked to neoplasm.